Hofseth Biocare

a Norwegian biotech running a patented continuous enzymatic hydrolysis of fresh (never-frozen) salmon heads and bones at the processing plant, yielding three zero-waste products — purified fish oil OmeGo, soluble protein hydrolysate ProGo and joint calcium powder CalGo.

Country: Norway
Ticker: HBC.OL

ISO 22000 GMP

Coverage

	CN	EU	US
aquaculture-seafood	✓	✓	✓

Regulatorsfdaefsanmpa

Verifiable facts

Fact	Value	Source
Funding	Raised 158 million NOK in a private placement and sold a stake in AecorBio Inc. for USD 5 million (Q4 2025); previously raised 10 million EUR from Aqua-Spark (2021) and 5 million EUR loan from Symrise (2025)	hofsethbiocare.com · live.euronext.com · seafoodsource.com
Capacity	Midsund facility has an annualized processing capacity of approximately 24,000 metric tonnes of raw material	hofsethbiocare.com · ml-eu.globenewswire.com
Certification	Laboratory in Midsund certified to ISO 17025 standards; facilities also align with GLOBALG.A.P. standards for aquaculture production	live.euronext.com
Regulatory approval	Secured ingredient approvals in Australia and South Korea (2025); has existing US and EU regulatory frameworks for health claims	live.euronext.com · ml-eu.globenewswire.com
Production site	Operating facility in Midsund; constructing a second facility in Berkåk, Norway	hofsethbiocare.com · uk.finance.yahoo.com · seafoodsource.com
Headcount	78 to 83 employees as of end of 2024/2025	companybook.co · live.euronext.com · stockanalysis.com
Revenue	256.3 million NOK for the full year 2025	live.euronext.com · ml-eu.globenewswire.com

Independent sources: companybook.co · live.euronext.com · ml-eu.globenewswire.com · seafoodsource.com · stockanalysis.com · uk.finance.yahoo.com

Technologies

Name	Cluster	Risk
Marine peptides & nutraceuticals	aquaculture-seafood	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.